Precision pharmacology for Alzheimer's disease.

[1]  J. Cummings,et al.  Repurposed agents in the Alzheimer’s disease drug development pipeline , 2020, Alzheimer's Research & Therapy.

[2]  Carolini Mendes,et al.  Gold Nanoparticles Treatment Reverses Brain Damage in Alzheimer’s Disease Model , 2019, Molecular Neurobiology.

[3]  G. Fink,et al.  Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD , 2019, NeuroImage: Clinical.

[4]  H. Hampel,et al.  Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease
 , 2019, Dialogues in clinical neuroscience.

[5]  S. Strittmatter,et al.  Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model , 2018, Neuropharmacology.

[6]  Xiongwei Zhu,et al.  NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease , 2018, Molecular Neurobiology.

[7]  M. Trincavelli,et al.  α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects , 2017, Molecular Neurobiology.

[8]  K. Blennow,et al.  24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial , 2017, The Lancet Neurology.

[9]  C. Jack,et al.  Midlife systemic inflammatory markers are associated with late-life brain volume , 2017, Neurology.

[10]  E. Rizzarelli,et al.  Amyloid Beta monomers regulate cyclic adenosine monophosphate response element binding protein functions by activating type‐1 insulin‐like growth factor receptors in neuronal cells , 2017, Aging cell.

[11]  P. Fraser,et al.  Impaired peripheral glucose homeostasis and Alzheimer's disease , 2017, Neuropharmacology.

[12]  A. Cuello.  Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum? , 2017, Trends in pharmacological sciences.

[13]  C. Masters,et al.  A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain , 2017, Nature Reviews Neurology.

[14]  A. Mørk,et al.  Antagonism of the 5-HT6 receptor – Preclinical rationale for the treatment of Alzheimer's disease , 2017, Neuropharmacology.

[15]  K. Keeshan,et al.  Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. , 2017, Experimental Hematology.

[16]  Gonzalo A. Bello,et al.  Toward Personalized Network Biomarkers in Alzheimer's Disease: Computing Individualized Genomic and Protein Crosstalk Maps , 2017, Front. Aging Neurosci..

[17]  D. Centonze,et al.  Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis , 2017, Neurology.

[18]  Anne K. Braczynski,et al.  Vaccination strategies in tauopathies and synucleinopathies , 2017, Journal of neurochemistry.

[19]  N. Toschi,et al.  Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease , 2017, Alzheimer's & Dementia.

[20]  N. Toschi,et al.  Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease , 2017, Neurochemistry International.

[21]  N. Scarmeas,et al.  Mediterranean diet and cognitive health: Initial results from the Hellenic Longitudinal Investigation of Ageing and Diet , 2017, PloS one.

[22]  R. Bateman,et al.  Stop Alzheimer’s before it starts , 2017, Nature.

[23]  M. Mattson,et al.  Brain metabolism in health, aging, and neurodegeneration , 2017, The EMBO journal.

[24]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2017 , 2017, Alzheimer's & dementia.

[25]  J. Hardy,et al.  Membrane damage is at the core of Alzheimer's disease , 2017, The Lancet Neurology.

[26]  Alzheimer's Disease Neuroimaging Initiative.  Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .

[27]  C. Parsons,et al.  Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease , 2017, Expert opinion on investigational drugs.

[28]  H. Hampel,et al.  Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases , 2017, Expert review of proteomics.

[29]  Hülya Bayır,et al.  The far-reaching scope of neuroinflammation after traumatic brain injury , 2017, Nature Reviews Neurology.

[30]  Asher Mullard.  BACE inhibitor bust in Alzheimer trial , 2017, Nature Reviews Drug Discovery.

[31]  Sherif Hamed.  Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications , 2017, Expert review of clinical pharmacology.

[32]  Abdul Rasheed Mohammed,et al.  Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease. , 2017, Journal of medicinal chemistry.

[33]  D. Rujescu,et al.  Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer’s Disease Dementia in Individuals With Mild Cognitive Impairment , 2017, Biological Psychiatry.

[34]  B. Dubois,et al.  A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling , 2017, Climacteric : the journal of the International Menopause Society.

[35]  A. Crisp,et al.  Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease , 2017, Journal of neurochemistry.

[36]  Stanislav Katina,et al.  Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial , 2017, The Lancet Neurology.

[37]  P. Pietrini,et al.  Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study , 2017, Scientific Reports.

[38]  G. Grossberg,et al.  Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease , 2017, Expert opinion on emerging drugs.

[39]  M. Sand,et al.  A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers , 2017, Human psychopharmacology.

[40]  P. Snyder,et al.  Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic , 2017, Alzheimer's & Dementia.

[41]  J. Vickers,et al.  Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease , 2016, Alzheimer's & dementia.

[42]  M. Filippi,et al.  Does neuroinflammation sustain neurodegeneration in ALS? , 2016, Neurology.

[43]  J. Cummings,et al.  Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease , 2016, Alzheimer's & dementia.

[44]  B. Dubois,et al.  PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.

[45]  J. Quevedo,et al.  The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease. , 2016, Current Alzheimer research.

[46]  Claudio Soto,et al.  Molecular interaction between type 2 diabetes and Alzheimer’s disease through cross-seeding of protein misfolding , 2016, Molecular Psychiatry.

[47]  H. Malkki.  Multiple sclerosis: Coagulation factors could mediate neuroinflammation in multiple sclerosis , 2016, Nature Reviews Neurology.

[48]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[49]  R. Quirion,et al.  Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model , 2016, Neurobiology of Aging.

[50]  Philip S. Insel,et al.  Plasma tau in Alzheimer disease , 2016, Neurology.

[51]  Jeremy M. Berg.  Gene-environment interplay , 2016, Science.

[52]  T. Foltynie,et al.  Insulin resistance and Parkinson’s disease: A new target for disease modification? , 2016, Progress in Neurobiology.

[53]  J. Trojanowski,et al.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges , 2016, Alzheimer's & Dementia.

[54]  David S. Miller,et al.  Tau: From research to clinical development , 2016, Alzheimer's & Dementia.

[55]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[56]  N. Toschi,et al.  Biomarker-guided classification scheme of neurodegenerative diseases , 2016, Journal of sport and health science.

[57]  D. Brough,et al.  Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models , 2016, Nature Communications.

[58]  K. Gannon,et al.  NPT088 reduces both amyloid-β and tau pathologies in transgenic mice , 2016, Alzheimer's & dementia.

[59]  J. Wiltfang,et al.  Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease , 2015, Molecular Neurobiology.

[60]  C. Lemere,et al.  Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges , 2016, Molecular Neurodegeneration.

[61]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[62]  William D. Dunn,et al.  Applicability of digital analysis and imaging technology in neuropathology assessment , 2016, Neuropathology : official journal of the Japanese Society of Neuropathology.

[63]  C. Barbas,et al.  Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment. , 2016, Current Alzheimer research.

[64]  R. Marconi,et al.  Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study , 2016, Alzheimer's & Dementia.

[65]  Hiroyuki Kubota,et al.  Trans-Omics: How To Reconstruct Biochemical Networks Across Multiple 'Omic' Layers. , 2016, Trends in biotechnology.

[66]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[67]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[68]  V. Yong,et al.  Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. , 2016, Brain : a journal of neurology.

[69]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[70]  R. Kolamunnage-Dona,et al.  Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review , 2016, PloS one.

[71]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[72]  J. Hardy,et al.  Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease , 2016, Current Opinion in Neurobiology.

[73]  Stephen F. Carter,et al.  Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease , 2016, Brain : a journal of neurology.

[74]  A. Arnsten,et al.  Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders. , 2016, Annual review of pharmacology and toxicology.

[75]  J. Burns,et al.  Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[76]  L. Wilkins.  Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial , 2015, Neurology.

[77]  D. Rujescu,et al.  The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease , 2015, Alzheimer's & Dementia.

[78]  Dean P. Jones.  Sequencing the exposome: A call to action , 2015, Toxicology reports.

[79]  M. Nalls,et al.  Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease , 2015, Front. Neurol..

[80]  A. Bespalov,et al.  Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease , 2015, Expert opinion on investigational drugs.

[81]  D. Holtzman,et al.  microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain , 2015, The Journal of Neuroscience.

[82]  V. Haroutunian,et al.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia , 2015, Alzheimer's & Dementia.

[83]  Yan Yang,et al.  Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice , 2015, Journal of neurochemistry.

[84]  T. Morgan,et al.  Astrocytic estrogen receptors and impaired neurotrophic responses in a rat model of perimenopause , 2015, Front. Aging Neurosci..

[85]  P. Spano,et al.  CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid , 2015, Neuroscience.

[86]  Steven H. Liang,et al.  Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease. , 2015, ACS medicinal chemistry letters.

[87]  You-Qiang Song,et al.  Inflammation in Alzheimer’s Disease and Molecular Genetics: Recent Update , 2015, Archivum Immunologiae et Therapiae Experimentalis.

[88]  Thomas Wisniewski,et al.  Clearance systems in the brain—implications for Alzheimer disease , 2015, Nature Reviews Neurology.

[89]  Zhigang Zhang,et al.  Inflammation in Alzheimer’s Disease and Molecular Genetics: Recent Update , 2015, Archivum Immunologiae et Therapiae Experimentalis.

[90]  John Didsbury,et al.  T3D-959: A multi-faceted disease remedial drug candidate for the treatment of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[91]  H. Hampel,et al.  Lithium as a treatment for Alzheimer’s disease: A systematic review and meta-analysis , 2015, Alzheimer's & Dementia.

[92]  G. Kemmler,et al.  The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment , 2015, Alzheimer's & dementia.

[93]  M. Clerici.  Faculty Opinions recommendation of Structural and functional features of central nervous system lymphatic vessels. , 2015 .

[94]  H. Gürvit,et al.  The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease , 2015, Journal of Neuroimmunology.

[95]  F. Salituro,et al.  Allopregnanolone Preclinical Acute Pharmacokinetic and Pharmacodynamic Studies to Predict Tolerability and Efficacy for Alzheimer’s Disease , 2015, PloS one.

[96]  A. Camins,et al.  Masitinib for the treatment of mild to moderate Alzheimer’s disease , 2015, Expert review of neurotherapeutics.

[97]  J. Fagerness,et al.  Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders , 2015, Genetics research.

[98]  S. Strittmatter,et al.  Fyn inhibition rescues established memory and synapse loss in Alzheimer mice , 2015, Annals of neurology.

[99]  E. Sigurdsson,et al.  Tau immunotherapy for Alzheimer's disease. , 2015, Trends in molecular medicine.

[100]  V. Perry,et al.  Etanercept in Alzheimer disease , 2015, Neurology.

[101]  S. Gori,et al.  Migraine features in migraineurs with and without anxiety–depression symptoms: A hospital-based study , 2015, Clinical Neurology and Neurosurgery.

[102]  A. Fagan,et al.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research , 2015, Alzheimer's & Dementia.

[103]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[104]  B. Hyman,et al.  Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation , 2015, Cell Death and Differentiation.

[105]  Premchand Gupta,et al.  Role of Traditional Nonsteroidal Anti-inflammatory Drugs in Alzheimer’s Disease , 2015, American journal of Alzheimer's disease and other dementias.

[106]  D. Holtzman,et al.  TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model , 2015, Cell.

[107]  A. Lucia,et al.  Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect , 2015, Drugs & Aging.

[108]  Gang Yuan,et al.  Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats With Type 2 Diabetes , 2015, Journal of Investigative Medicine.

[109]  W. Schmidt,et al.  Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines , 2015, PloS one.

[110]  L. Pantoni,et al.  Development and psychometric properties of a neuropsychological battery for mild cognitive impairment with small vessel disease: the VMCI-Tuscany Study. , 2014, Journal of Alzheimer's disease : JAD.

[111]  B. Hyman,et al.  A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease* , 2014, The Journal of Biological Chemistry.

[112]  D. Loeffler.  Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered? , 2014, Journal of Neuroinflammation.

[113]  F. Fahrenholz,et al.  Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin , 2014, Neurology.

[114]  Miles Miller,et al.  Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits , 2014, PloS one.

[115]  B. Strooper,et al.  Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.

[116]  A. Cuello,et al.  Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease , 2014, Neurobiology of Aging.

[117]  K Broich,et al.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. , 2014, The journal of prevention of Alzheimer's disease.

[118]  Danielle A. Simmons,et al.  A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression , 2014, PloS one.

[119]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[120]  J. Molinuevo,et al.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis , 2014, Science Translational Medicine.

[121]  J. Hardy,et al.  A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.

[122]  R. Shah,et al.  An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease , 2014, Current Alzheimer research.

[123]  A. Lo,et al.  Parallel Discovery of Alzheimer’s Therapeutics , 2014, Science Translational Medicine.

[124]  A. Cheema,et al.  The critical need for defining preclinical biomarkers in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[125]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[126]  U. Bonuccelli,et al.  Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. , 2014, Parkinsonism & related disorders.

[127]  Geoffrey S Ginsburg,et al.  Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity. , 2014, JAMA.

[128]  S. Hickman,et al.  TREM2 and the neuroimmunology of Alzheimer's disease. , 2014, Biochemical pharmacology.

[129]  J. Ávila,et al.  New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. , 2014, Biochemical pharmacology.

[130]  Olivier Colliot,et al.  Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. , 2014, Biochemical pharmacology.

[131]  W. Xu,et al.  Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. , 2014, Journal of proteome research.

[132]  C. Hölscher.  Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. , 2014, The Journal of endocrinology.

[133]  Yan-Jiang Wang,et al.  Alzheimer disease: Lessons from immunotherapy for Alzheimer disease , 2014, Nature Reviews Neurology.

[134]  David A. Bennett,et al.  REST and Stress Resistance in Aging and Alzheimer’s Disease , 2014, Nature.

[135]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[136]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[137]  J. P. de Rivero Vaccari,et al.  Activation and Regulation of Cellular Inflammasomes: Gaps in Our Knowledge for Central Nervous System Injury , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[138]  D. Cribbs,et al.  Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines , 2014, Human vaccines & immunotherapeutics.

[139]  V. Lee,et al.  Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases , 2014, Nature Medicine.

[140]  H. Soininen,et al.  Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease , 2014, Neurobiology of Aging.

[141]  Abbas Ali Mahdi,et al.  Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.

[142]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[143]  C. Power,et al.  Inflammasomes in the CNS , 2014, Nature Reviews Neuroscience.

[144]  T. Golde.  Open questions for Alzheimer’s disease immunotherapy , 2014, Alzheimer's Research & Therapy.

[145]  P. Séguéla,et al.  Inhibition of P2X4 function by P2Y6 UDP receptors in microglia , 2013, Glia.

[146]  M. Ramanathan,et al.  Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.

[147]  P. Mcgeer,et al.  The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy , 2013, Acta Neuropathologica.

[148]  A. Jeromin,et al.  Calpain cleavage and inactivation of the sodium calcium exchanger-3 occur downstream of Aβ in Alzheimer’s disease , 2013, Aging cell.

[149]  F. van Leuven,et al.  Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.

[150]  William A Banks,et al.  Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[151]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[152]  D. Nicholson,et al.  The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques , 2013, Acta Neuropathologica.

[153]  R. Brinton,et al.  Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments , 2013, Brain Research.

[154]  J. Schnell,et al.  Characterization of the Human Sigma-1 Receptor Chaperone Domain Structure and Binding Immunoglobulin Protein (BiP) Interactions* , 2013, The Journal of Biological Chemistry.

[155]  S. Horvath,et al.  Genes and pathways underlying regional and cell type changes in Alzheimer's disease , 2013, Genome Medicine.

[156]  E. Latz,et al.  Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.

[157]  Keith A. Johnson,et al.  CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.

[158]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[159]  Ronald C. Petersen,et al.  Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics , 2013, PloS one.

[160]  Ajit S. Divakaruni,et al.  Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins , 2013, PloS one.

[161]  L. Ferraro,et al.  Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice , 2013, BMC Neuroscience.

[162]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[163]  Zöe Corbyn.  New set of Alzheimer's trials focus on prevention , 2013, The Lancet.

[164]  Jennifer L. Harris,et al.  Enhanced Proteolytic Clearance of Plasma Aβ by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain Aβ in Mice , 2013, The Journal of Neuroscience.

[165]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[166]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[167]  M. Daly,et al.  Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.

[168]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[169]  M. Heneka,et al.  NLRP3 is activated in Alzheimer´s disease and contributes to pathology in APP/PS1 mice , 2012, Nature.

[170]  B. de Strooper,et al.  Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice , 2012, Molecular Neurodegeneration.

[171]  Ela Patel,et al.  Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes. , 2012, Journal of neuropathology and experimental neurology.

[172]  A. Monsch,et al.  Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study , 2012, Alzheimer's Research & Therapy.

[173]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[174]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[175]  E. Siemers,et al.  Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[176]  M. Kaeberlein,et al.  Ageing: A healthy diet for stem cells , 2012, Nature.

[177]  Veeranna,et al.  Calpastatin modulates APP processing in the brains of β-amyloid depositing but not wild-type mice , 2012, Neurobiology of Aging.

[178]  M. Ferretti,et al.  Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology , 2012, Journal of Neuroinflammation.

[179]  Zehong Wan,et al.  γ‐Secretase modulators do not induce Aβ‐rebound and accumulation of β‐C‐terminal fragment , 2012, Journal of neurochemistry.

[180]  M. Youdim,et al.  Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. , 2012, Current drug targets.

[181]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[182]  R. Iyengar,et al.  Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.

[183]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[184]  Mathias Jucker,et al.  The Amyloid State of Proteins in Human Diseases , 2012, Cell.

[185]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[186]  Y. Oda,et al.  Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology[S] , 2012, Journal of Lipid Research.

[187]  N. Tabet,et al.  Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. , 2012, The Cochrane database of systematic reviews.

[188]  F. Panza,et al.  Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease , 2012, Expert review of clinical immunology.

[189]  Xi-jun Wang,et al.  Modern analytical techniques in metabolomics analysis. , 2012, The Analyst.

[190]  J. Slodkowska,et al.  Digital pathology in personalized cancer therapy. , 2012, Folia histochemica et cytobiologica.

[191]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[192]  N. Belyaev,et al.  Are amyloid‐degrading enzymes viable therapeutic targets in Alzheimer’s disease? , 2012, Journal of neurochemistry.

[193]  A. Fisher.  Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease , 2012, Journal of neurochemistry.

[194]  S. Weggen,et al.  Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer’s Disease , 2011, Current neuropharmacology.

[195]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[196]  K. Blennow,et al.  Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease , 2011, Molecular Neurodegeneration.

[197]  S. Gray.  Epigenetic treatment of neurological disease. , 2011, Epigenomics.

[198]  G. Landreth,et al.  Nuclear receptors as therapeutic targets for Alzheimer's disease , 2011, Expert opinion on therapeutic targets.

[199]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Cancer.

[200]  W. Wurst,et al.  Telomere shortening reduces Alzheimer's disease amyloid pathology in mice. , 2011, Brain : a journal of neurology.

[201]  R. Green,et al.  Extended results of the Alzheimer’s disease anti-inflammatory prevention trial , 2011, Alzheimer's & Dementia.

[202]  Jian-Quan Shi,et al.  COGNITIVE IMPROVEMENT WITH INTRATHECAL ADMINISTRATION OF INFLIXIMAB IN A WOMAN WITH ALZHEIMER'S DISEASE , 2011, Journal of the American Geriatrics Society.

[203]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[204]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Neuroscience.

[205]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[206]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[207]  T. Coté,et al.  Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. , 2011, Discovery medicine.

[208]  G. Manning,et al.  Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB , 2011, Nature.

[209]  L. Farrer,et al.  Power and Pitfalls of the Genome-Wide Association Study Approach to Identify Genes for Alzheimer’s Disease , 2011, Current psychiatry reports.

[210]  P. Magistretti,et al.  Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 Species* , 2010, The Journal of Biological Chemistry.

[211]  V. Haroutunian,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[212]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[213]  P. Foley.  Lipids in Alzheimer's disease: A century-old story. , 2010, Biochimica et biophysica acta.

[214]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[215]  K. Blennow,et al.  Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism , 2010, BMC neurology.

[216]  Linda Partridge,et al.  Extending Healthy Life Span—From Yeast to Humans , 2010, Science.

[217]  C. Kenyon.  The genetics of ageing , 2010, Nature.

[218]  C. Dinarello.  Anti-inflammatory Agents: Present and Future , 2010, Cell.

[219]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[220]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[221]  E. Siemers,et al.  Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease , 2010, Clinical neuropharmacology.

[222]  G. D. Paolo,et al.  Faculty Opinions recommendation of Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. , 2010 .

[223]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[224]  J. Hoeijmakers.  DNA damage, aging, and cancer. , 2009, The New England journal of medicine.

[225]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[226]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[227]  Janet M. Thornton,et al.  Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.

[228]  A. Cuello,et al.  Amyloid &bgr;-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease , 2009, Journal of neuropathology and experimental neurology.

[229]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[230]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[231]  E. Siemers,et al.  Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease , 2009, Expert Opinion on Pharmacotherapy.

[232]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[233]  D. Selkoe,et al.  Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening , 2009, PloS one.

[234]  F. LaFerla,et al.  Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology , 2009, Neurobiology of Disease.

[235]  T. Golde,et al.  Quantitative and Mechanistic Studies of Aβ Immunotherapy , 2009 .

[236]  C. Adler,et al.  Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[237]  J. Hoeijmakers,et al.  DNA damage and ageing: new-age ideas for an age-old problem , 2008, Nature Cell Biology.

[238]  Michael G. Yang,et al.  The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression* , 2008, Journal of Biological Chemistry.

[239]  G. Landreth,et al.  PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease , 2008, Neurotherapeutics.

[240]  F. Schweighoffer,et al.  Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing , 2008, Journal of neurochemistry.

[241]  D. Pozo,et al.  Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics , 2008, Journal of cellular and molecular medicine.

[242]  S. Hendrix,et al.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.

[243]  E. Tobinick.  INFLAMMATORY MARKERS AND THE RISK OF ALZHEIMER DISEASE: THE FRAMINGHAM STUDY , 2008, Neurology.

[244]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[245]  C. Sanders,et al.  Substrate specificity of γ-secretase and other intramembrane proteases , 2008, Cellular and Molecular Life Sciences.

[246]  M. Pangalos,et al.  Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse , 2008, Neurodegenerative Diseases.

[247]  E. Siemers,et al.  Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-&bgr; After Inhibition of &ggr;-Secretase , 2007 .

[248]  D. Galasko,et al.  Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals , 2007, Alzheimer disease and associated disorders.

[249]  Rena Li,et al.  Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. , 2007, The Journal of cell biology.

[250]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[251]  Rena Li,et al.  Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice , 2007, The Journal of Cell Biology.

[252]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[253]  K. Jellinger,et al.  Neuropathological evaluation of mixed dementia , 2007, Journal of the Neurological Sciences.

[254]  D. Riesner,et al.  Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice , 2007, Proceedings of the National Academy of Sciences.

[255]  M. Michaelis,et al.  Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. , 2007, European journal of pharmacology.

[256]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[257]  Tracy M. Brown,et al.  Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[258]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[259]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[260]  Madhusudan Natarajan,et al.  A global analysis of cross-talk in a mammalian cellular signalling network , 2006, Nature Cell Biology.

[261]  E. Tobinick,et al.  TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. , 2006, MedGenMed : Medscape general medicine.

[262]  M. Reger,et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[263]  Amir Gamliel,et al.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ , 2005, Nature.

[264]  P. Lewczuk,et al.  Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? , 2005, Journal of psychiatric research.

[265]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[266]  L. Lue,et al.  Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. , 2005, Current drug targets. CNS and neurological disorders.

[267]  P. May,et al.  P4-339 Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor , 2004, Neurobiology of Aging.

[268]  P. May,et al.  P2-053 Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months , 2004, Neurobiology of Aging.

[269]  C. Cotman,et al.  Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. , 2004, The Journal of clinical investigation.

[270]  P. May,et al.  P1-419 In vivo characterization of LY450139, a novel, stereoselective, functional gamma-secretase inhibitor , 2004, Neurobiology of Aging.

[271]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[272]  Dai Zhang,et al.  Tumor Necrosis Factor Death Receptor Signaling Cascade Is Required for Amyloid-β Protein-Induced Neuron Death , 2004, The Journal of Neuroscience.

[273]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[274]  H. Möller,et al.  Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[275]  Takashi Morihara,et al.  Selective inhibition of Aβ42 production by NSAID R‐enantiomers , 2002 .

[276]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[277]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[278]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[279]  Patrick L. McGeer,et al.  Inflammation, autotoxicity and Alzheimer disease , 2001, Neurobiology of Aging.

[280]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[281]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[282]  B. Yankner,et al.  Inflammation and Alzheimer disease: The good, the bad, and the ugly , 2001, Nature Medicine.

[283]  A. Gal.  In Search of the Origins of Modern Surgical Pathology , 2001, Advances in anatomic pathology.

[284]  D. Selkoe,et al.  Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein , 2000, Annals of the New York Academy of Sciences.

[285]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[286]  A. Smith,et al.  Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. , 1998, Alzheimer disease and associated disorders.

[287]  H. Möller,et al.  Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease , 1998, Brain Research.

[288]  V. Singh,et al.  Circulating cytokines in Alzheimer's disease. , 1997, Journal of psychiatric research.

[289]  E. Matsubara,et al.  Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β , 1997, Journal of neurochemistry.

[290]  T. Duong,et al.  C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease , 1997, Brain Research.

[291]  J. Trojanowski,et al.  Microtubule stabilizing drugs for the treatment of Alzheimer's disease , 1994, Neurobiology of Aging.

[292]  H. Arai,et al.  Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections , 1994, Neuroscience Letters.

[293]  M. Brouns,et al.  Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness? , 1992, Brain Research.

[294]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[295]  D. Betcher,et al.  Granulocyte macrophage colony-stimulating factor , 1991, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[296]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[297]  P. Mcgeer,et al.  Anti-inflammatory drugs and Alzheimer disease , 1990, The Lancet.

[298]  A. Hofman,et al.  Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease , 1990, Neuroscience Letters.

[299]  K. Ogomori,et al.  Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. , 1989, The American journal of pathology.

[300]  P. Fraser,et al.  The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-β, Amylin, and Tau Proteins. , 2017, Journal of Alzheimer's disease : JAD.

[301]  K. Blackburn,et al.  Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease. , 2017, The journal of prevention of Alzheimer's disease.

[302]  Simone Lista,et al.  Evolving Relevance of Neuroproteomics in Alzheimer's Disease. , 2017, Methods in molecular biology.

[303]  R. Courtney.  NUCLEAR RECEPTORS AS THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE , 2017 .

[304]  Simone Lista,et al.  Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. , 2016, Methods in molecular biology.

[305]  S. Monte.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease , 2016, Drugs.

[306]  A. Wall,et al.  Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. , 2015, Journal of Alzheimer's disease : JAD.

[307]  M. Danik,et al.  The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[308]  Tianning Liui,et al.  The role of TREM 2 R 47 H as a risk factor for Alzheimer ’ s disease , frontotemporal lobar degeneration , amyotrophic lateral sclerosis , and Parkinson ’ s disease , 2015 .

[309]  T. Arendt,et al.  Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[310]  P. Scheltens,et al.  A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[311]  M. Bulyk,et al.  Gene Regulatory Networks , 2013 .

[312]  J. Searcy,et al.  Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[313]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[314]  J. Kaye,et al.  The ageing systemic milieu negatively regulates neurogenesis and cognitive function , 2011 .

[315]  Rena Li,et al.  Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. , 2010, Journal of Alzheimer's disease : JAD.

[316]  T. Golde,et al.  Quantitative and mechanistic studies of Abeta immunotherapy. , 2009, CNS & neurological disorders drug targets.

[317]  E. Siemers,et al.  Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. , 2007, Clinical neuropharmacology.

[318]  Tracy M. Brown,et al.  Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. , 2006, The Journal of pharmacology and experimental therapeutics.

[319]  F. LaFerla,et al.  Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice , 2005, Journal of Neuroinflammation.

[320]  A. Passmore,et al.  Untargeted Metabolomic Analysis of Human Plasma Indicates Differentially Affected Polyamine and L-Arginine Metabolism in Mild Cognitive Impairment Subjects Converting to Alzheimer’s Disease , 2015, PloS one.

[321]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[322]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[323]  G. Cole,et al.  Selective inhibition of Abeta42 production by NSAID R-enantiomers. , 2002, Journal of neurochemistry.

[324]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[325]  Mark S. Shearman,et al.  Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .

[326]  R. Stelzmann,et al.  An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde” , 1995 .

[327]  M. Goedert,et al.  The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease. , 1989, Annals of medicine.